William P. Powell's most recent trade in Apartment Investment & Management Co. - Ordinary Shares - Class A was a trade of 89,814 Class A Common Stock done at an average price of $7.7 . Disclosure was reported to the exchange on April 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apartment Investment | Wesley William Powell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.70 per share. | 15 Apr 2025 | 89,814 | 618,455 | - | 7.7 | 691,568 | Class A Common Stock |
| Apartment Investment | Wesley William Powell | Director, President and CEO | 15 Apr 2025 | 3 | 49 | - | 9 | 27 | Class A Common Stock | |
| Apartment Investment | Wesley William Powell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.04 per share. | 02 Feb 2025 | 58,218 | 708,269 | - | 9.0 | 526,291 | Class A Common Stock |
| Apartment Investment | Wesley William Powell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 312,877 | 947,277 | - | - | Stock Option (right to buy) | |
| Apartment Investment | Wesley William Powell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 120,535 | 683,896 | - | - | Class A Common Stock | |
| Apartment Investment | Wesley William Powell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 82,591 | 766,487 | - | - | Class A Common Stock | |
| Apartment Investment | Wesley William Powell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.93 per share. | 27 Jan 2025 | 30,651 | 563,361 | - | 8.9 | 273,713 | Class A Common Stock |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 33,523 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Purchase of securities on an exchange or from another person at price $ 1.23 per share. | 01 Mar 2024 | 8,500 | 22,863 (0%) | 0% | 1.2 | 10,455 | Common Stock |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Purchase of securities on an exchange or from another person at price $ 1.25 per share. | 01 Mar 2024 | 6,000 | 28,863 (0%) | 0% | 1.3 | 7,500 | Common Stock |
| Apartment Investment | William Wesley Powell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 634,400 | 634,400 | - | - | Stock Option (right to buy) | |
| Apartment Investment | Wesley Powell William | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 179,858 | 594,012 | - | - | Class A Common Stock | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 14,363 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Consol Energy Inc | William P. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 4,694 | 130,088 (0%) | 0% | 0 | Common stock, par value $0.01 per share | |
| Apartment Investment | Wesley William Powell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 5,125 | 414,154 | - | - | Class A Common Stock | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 9.50 per share. | 04 Jun 2022 | 7,059 | 27,477 (0%) | 0% | 9.5 | 67,061 | Common Stock |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2022 | 7,059 | 0 | - | - | Restricted Stock Unit | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 13,856 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Jun 2022 | 709 | 10,500 (0%) | 0% | 0 | Common Stock | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 9,474 | 9,474 | - | - | Restricted Stock Unit | |
| Consol Energy Inc | William P. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 6,124 | 125,394 (0%) | 0% | 0 | Common stock, par value $0.01 per share | |
| Apartment Investment | Wesley William Powell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 2,658 | 409,029 | - | - | Class A Common Stock | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 7,059 | 7,059 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 8,303 | 0 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 11.64 per share. | 01 Jun 2021 | 8,303 | 20,418 (0%) | 0% | 11.6 | 96,647 | Common Stock |
| Consol Energy Inc | William P. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 28,355 | 119,270 (0%) | 0% | 0 | Common stock, par value $0.01 per share | |
| Apartment Investment | Wesley William Powell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 371,901 | 406,371 | - | - | Class A Common Stock | |
| Apartment Investment | Wesley William Powell | Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 15 Apr 2021 | 206 | 34,470 | - | - | Class A Common Stock | |
| FMC Corp | William H. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 64 | 17,202 (0%) | 0% | 0 | Common Stock | |
| Apartment Investment | Wesley William Powell | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2020 | 3,737 | 34,264 | - | - | Class A Common Stock | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,200 | 0 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 10.36 per share. | 15 Oct 2020 | 2,200 | 12,115 (0%) | 0% | 10.4 | 22,792 | Common Stock |
| FMC Corp | William H. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2020 | 63 | 17,138 (0%) | 0% | 0 | Common Stock |